Abdelhadi Rifai
Cardiovascular Disease · Park Ridge, ILNPI 1588047245
Payments from drug & device makers
Across 182 payments — averaging $66.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Boston Scientific$2K
- Boehringer Ingelheim$300
- Abiomed$252
- Pfizer$208
- Abbott$194
- plus $2K from 35 others
Across 1 payment — averaging $68.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$69
What the payments were for
- Grants$7,00058%
- Travel & lodging$6786%
- Food & beverage$4,40436%
- Education$821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $7,040 |
| Boston Scientific | 49 | $2,057 |
| Boehringer Ingelheim | 14 | $300 |
| Abiomed | 7 | $252 |
| Pfizer | 11 | $208 |
| Abbott | 8 | $194 |
| Penumbra, Inc. | 2 | $188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $177 |
| Novartis | 10 | $171 |
| Johnson & Johnson | 5 | $126 |
| Heartflow, Inc. | 4 | $119 |
| Novo Nordisk | 5 | $99 |
| Amgen | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Siemens Medical Solutions USA, Inc. | 2 | $77 |
| Alnylam Pharmaceuticals Inc. | 4 | $72 |
| ZOLL Circulation Inc | 3 | $66 |
| Sanofi-aventis U.S. LLC | 2 | $65 |
| Biotronik Inc. | 3 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $64 |
| Edwards Lifesciences | 2 | $63 |
| AstraZeneca | 3 | $59 |
| Cardiva Medical, Inc. | 2 | $46 |
| Bayer | 3 | $45 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Merck | 3 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Biosense Webster, Inc. | 2 | $38 |
| Acist Medical Systems, Inc. | 1 | $34 |
| Cleerly, Inc. | 1 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $28 |
| Teleflex LLC | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Getinge USA Sales, LLC | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| EKOS Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,049
- Watchman$103
How this compares
$12,164 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $270,072 |
| FarxigaDapagliflozin Propanediol | 25 | $32,645 |
| EntrestoSacubitril/Valsartan | 17 | $29,205 |
| XareltoRivaroxaban | 14 | $19,877 |
| BrilintaTicagrelor | 21 | $11,539 |
| SavaysaEdoxaban Tosylate | 12 | $4,964 |
| Metoprolol Succinate | 232 | $4,088 |
| Atorvastatin Calcium | 249 | $3,155 |
| Losartan Potassium | 161 | $2,304 |
| Flecainide Acetate | 33 | $1,602 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $1,489 |
| Bumetanide | 24 | $1,253 |
| Spironolactone | 115 | $1,122 |
| Amlodipine Besylate | 126 | $1,076 |
| Lisinopril | 128 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $208 | $270,072254 claims |
| AstraZenecaFarxiga, Brilinta | $59 | $44,18446 claims |
| NovartisEntresto | $171 | $29,20517 claims |
| Johnson & JohnsonXarelto | $126 | $19,87714 claims |
| Daiichi Sankyo Inc.Savaysa | $42 | $4,96412 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $40 | $44415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Park Ridge
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.